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The emergence of multidrug-resistant pathogens
necessitates the search for new antibiotics acting
on previously unexplored targets. Nicotinate mono-
nucleotide adenylyltransferase of the NadD family,
an essential enzyme of NAD biosynthesis in most
bacteria, was selected as a target for structure-
based inhibitor development. Using iterative in silico
and in vitro screens, we identified small molecule
compounds that efficiently inhibited target enzymes
from Escherichia coli (ecNadD) and Bacillus anthra-
cis (baNadD) but had no effect on functionally equiv-
alent human enzymes. On-target antibacterial ac-
tivity was demonstrated for some of the selected
inhibitors. A 3D structure of baNadD was solved in
complexwith one of these inhibitors (3_02), providing
mechanistic insights and guidelines for further im-
provement. Most importantly, the results of this
study help validate NadD as a target for the develop-
ment of antibacterial agents with potential broad-
spectrum activity.
INTRODUCTION
The versatility and resourcefulness of microbes in developing
resistance to various therapies are widely recognized. Although
chemical modifications of existing drugs and the development of
novel inhibitors against a handful of previously established
targets have proven to be successful in the short term, it is
also apparent that newdrug targets need to be explored tomain-
tain and extend efficacious antibacterial therapy in the long run
(McDevitt and Rosenberg, 2001). The need for new targets is
further exacerbated by the emergence of bacterial pathogens
with natural resistance to existing antibiotics and by a potential
threat of pathogens with engineered antibiotic resistance.
Previous studies implicated NAD(P) biosynthesis as a prom-
ising, albeit relatively unexplored, target pathway for the devel-
opment of novel antimicrobial agents (Gerdes, et al., 2002;
Osterman and Begley, 2007; Sassetti, et al., 2003). Cofactors
of the NAD pool are indispensable as they are involved inChemistry & Biology 16, 8hundreds of redox reactions in the cell. Additionally, NAD is
utilized as a cosubstrate by a number of nonredox enzymes
(e.g., by bacterial DNA ligases and protein deacetylases of the
CobB/Sir2 family). This dictates the need to maintain NAD
homeostasis via its active resynthesis and recycling of NAD
degradation products. Recently, a number of insightful reviews
have emphasized the potential of NAD(P) biosynthetic enzymes
as drug targets for the treatment of cancer, autoimmune dis-
eases, and neurodegenerative disorders (Chen, et al., 2008;
Khan, et al., 2007; Lau, et al., 2009; Magni, et al., 2009). Although
the early steps in NAD biogenesis and recycling vary substan-
tially between species, the enzymes driving the downstream
conversion of nicotinic acid mononucleotide (NaMN) to NAD
and NADP are present in nearly all analyzed bacterial genomes
(Osterman and Begley, 2007; Sorci, et al., 2009) (Figure 1).
Therefore, all three enzymes of this pathway—NaMN adenylyl-
transferase (EC 2.7.7.18), NAD synthetase (EC 6.3.1.5), and
NAD kinase (EC 2.7.1.23)—encoded by the conserved genes
nadD, nadE, and nadK, represent promising broad-spectrum
antibacterial targets. The observed essentiality of the respective
genes is due to the bacteria being unable to uptake phosphory-
lated pyridine nucleotides (Gerdes, et al., 2002; Osterman and
Begley, 2007). Recent progress in the development of inhibitors
targeting the last two enzymes, NadE (Velu, et al., 2003; Velu,
et al., 2005; Velu, et al., 2007) and NadK (Bonnac, et al., 2007;
Poncet-Montange, et al., 2007), provides additional validation
of NAD biosynthesis as a target pathway. We have selected
the NadD enzyme as a target for the development of specific
inhibitors on the basis of a number of criteria such as essentiality,
broad conservation, and structure-function distinction from its
human counterpart (Gerdes, et al., 2002; Zhou, et al., 2002).
NadD converts NaMN, the first intermediate shared by the
most common de novo and salvage/recycling routes, to nicotinic
acid adenine dinucleotide (NaAD) (Figure 1). Therefore, this
enzyme should be indispensable in all bacterial species that
utilize one or both of these routes for NAD biosynthesis. This is
consistent with gene essentiality data for a number of bacterial
species (as reviewed in Gerdes, et al., 2006 and Gerdes, et al.,
2002). For example, the nadD gene was shown to be essential
for survival in Staphylococcus aureus and Streptococcus pneu-
moniae that are fully dependent on niacin salvage (via PncA-
PncB route). It is also essential in Escherichia coli andMycobac-
terium tuberculosis, organisms that harbor both the de novo49–861, August 28, 2009 ª2009 Elsevier Ltd All rights reserved 849
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Characterization of Bacterial NadD InhibitorsFigure 1. NAD(P)-Biosynthesis Pathways in Bacteria
NadD target enzyme is conserved in most bacteria. NaMN, a common biosynthetic intermediate in the salvage and de novo NAD biosynthetic pathways, is the
substrate for NadD. The ATP substrate acts as the adenylyl moiety donor for NaMN, yielding PPi and NaAD. The latter product is then amidated (and phosphor-
ylated) to give NAD and NADP.(NadB-NadA-NadC) and the salvage pathways. Remarkably, it
has been recently demonstrated that NAD downstream pathway
holds as an attractive target in both actively growing and nonrep-
licating pathogens (Boshoff, et al., 2008). NadD is present in
nearly all important pathogenswith only a few exceptional cases,
such as Haemophilus influenzae, which lacks most of NAD
biosynthetic machinery and is dependent on salvage of the so-
called V-factors (Gerlach and Reidl, 2006).
Many representatives of the NadD family from pathogenic and
model bacteria have been characterized mechanistically and
structurally (Han, et al., 2006; Lu, et al., 2008; Olland, et al.,
2002; Sershon, et al. 2009; Yoon, et al., 2005; Zhang, et al.,
2002). All of these enzymes have a strong substrate preference
for NaMN over its amidated analog, NMN. On the other hand,
all three isoforms of the functionally equivalent human enzyme
(hsNMNAT-1, hsNMNAT-2, and hsNMNAT-3) have an almost
equal catalytic efficiency for either substrate, NaMN or NMN
(Berger, et al., 2005; Sorci, et al., 2007). The observed difference
in substrate specificity reflects the dual physiological role of the
human enzyme (hereafter referred to as hsNMNAT) in the adeny-
lation of both intermediates contributing to NAD biogenesis (Lau,
et al., 2009; Magni, et al., 2008). Notably, among the three bacte-
rial enzymes of the target pathway shown in Figure 1, NadD has
the lowest sequence similarity to its human counterparts
(Gerdes, et al., 2002). Comparative analysis of 3D structures of
bacterial NadD and hsNMNAT revealed significant differences
between their active site conformations (Zhou, et al., 2002),
which are likely responsible for their distinct substrate specific-
ities, thus opening an opportunity for selective targeting.
The goals of the present study are to use a structure-based
approach to identify low-molecular-weight compounds that
selectively inhibit representative NadD enzymes, and to test
whether such inhibitors suppress the growth of model gram-
positive and gram-negative bacteria. Among the most important
results is the validation of the NadD family as a druggable target
whose specific inhibition leads to the suppression of bacterial
growth in culture. Detailed interactions between NadD enzyme
from Bacillus anthracis (baNadD) and one of the selected inhibi-
tors were revealed by the X-ray cocrystal structure, information
that will be instrumental in lead optimization and in development
of drug prototypes.850 Chemistry & Biology 16, 849–861, August 28, 2009 ª2009 ElsevRESULTS
An overview of the structure-based approach applied in this
study for NadD inhibitor discovery is summarized in Figure 2.
In silico screening of the large virtual library of low-molecular-
weight compounds to identify potential NadD inhibitors was per-
formed using the ecNadD structural template. Of the 500 top-
ranking in silico hits, 307 commercially available compounds
were subjected to in vitro primary testing for inhibition of two
representative target enzymes, ecNadD and baNadD. A series
of analogs of three high-ranking compounds of distinct chemo-
types (1, 3, and 15) active against both target enzymes were
characterized in more detail by both enzymatic and cell-based
assays. A cocrystal structure of baNadD in complex with one
of the inhibitors, 3_02, revealed atomic details of its interactions
with the enzyme active site, providing guidelines for future struc-
ture-based inhibitor optimization.
In Silico Screening of the Compound Library
The design of the template for in silico screening was based on
the 3D structure of ecNadD reported in our earlier study (Zhang,
et al., 2002). The targeted binding pocket encompassed the nic-
otinosyl binding site (near residues Asn40, Thr85, Phe104, and
Ile106 in ecNadD) as well as the catalytic site near the conserved
(H/T)xGH motif (around Phe8, Gly10, and His19). The initial
screen of 1 million compounds targeted a single conformation
of ecNadD in apo-form, which was followed by two rounds of
secondary screens. In the first round, 20,000 top-scoring com-
pounds selected in the initial screen were rescreened against
two additional apo-ecNadD conformations obtained from the
1k4k crystal structure (Zhang, et al., 2002). In the second round,
50,000 compounds from the initial screen were docked onto five
ecNadD conformations obtained from an MD simulation. Of the
500 top-scoring compounds selected by these two screens,
a total of 307 were purchased from vendors and were subjected
to experimental testing of their NadD inhibitory activity (see
Table S1 available online).
Experimental Testing of NadD Inhibitors
To evaluate the compounds obtained from virtual screening,
we experimentally tested their inhibitory activity against twoier Ltd All rights reserved
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Characterization of Bacterial NadD Inhibitorsrepresentative NadD target enzymes, from the model gram-
negative bacterium E. coli and from the gram-positive pathogen
B. anthracis. Both recombinant enzymes were overexpressed in
E. coli and were purified, and their steady-state kinetic parame-
ters were obtained using a standard coupled assay (Kurnasov,
et al., 2002). An extensive kinetic analysis of baNadD enzyme,
which included detection and exploration of negative coopera-
tivity, was recently published (Sershon, et al., 2009). The results
of our previously reported kinetic analysis of this enzyme, albeit
less detailed, yielded comparable steady state parameters that
reflect strong preference for NaMN over NMN (Sorci, et al.,
2009). A similar preference was observed for ecNadD (Table S2).
The experimental testing of selected compounds for their ability
to inhibit NaMNATase activity of NadD enzymes was performed
in the 96-well microtiter plate format using a colorimetric end-
point assay, which includes an enzymatic conversion of the
released PPi to Pi and a chromogenic reaction with the ammo-
nium molybdate/malachite green reagent (Cogan, et al., 1999).
At this stage of analysis, we aimed to detect inhibitors with
moderate affinity (e.g., IC50 at least 100 mM or better). Therefore,
for each of the two enzymes, the testing was performed in the
presence of compounds at 50–100 mM. The results of primary
Figure 2. Flowchart of the Structure-Based
Approach for Developing Bacterial NadD
Inhibitors
testing of all 307 compounds against
both enzymes are shown in Table S1. At
the 20% inhibition threshold, this method
identified 38 ecNadD inhibitors. Remark-
ably, the baNadD enzyme showed on
average a two-fold higher susceptibility
to inhibition, yielding 77 compounds at
the same threshold. An appreciable cor-
relation across the entire set of 307
analyzed compounds could be observed
in their inhibitory properties against both
enzymes (Table S1). This trend can be
best illustrated by the comparison of
two sets of 10% top-ranking ecNadD
and baNadD inhibitors revealing that
nearly one-third of them are shared be-
tween both sets (the estimated proba-
bility to get at least 12 random matches
is 3$1012, see Supplemental Data). This
observation indicated that the applied
in silico screening strategy was indeed
successful in targeting NadD active-site
components conserved between quite
divergent representatives of this enzyme
family. By combining this strategy with
the parallel experimental testing of com-
pounds against two divergent target
enzymes, we were able to identify 12
potentially broad-spectrum NadD inhibi-
tors. Three of these inhibitors (1, 3, and
15) with distinct scaffolds were selected
for further analysis, including characterization of their analogs
by enzymatic and cell-based assays and cocrystallization trials.
Selection and Comparative Analysis of NadD Inhibitor
Analogs
Tovalidate and further explore theutility of the threeselectedche-
motypes, structurally similar and commercially available analogs
of compounds 1, 3, and 15were identified using chemical finger-
print–based similarity analysis (Butina, 1999; Godden, et al.,
2005). For each of the primary compounds, 15 to 40 analogs
werepurchasedandanalyzedby thesame inhibitory assay. Inhib-
itory activity above a 20% threshold against at least one of the
analyzed NadD enzymes was confirmed for 66 of the 89 analogs
(Table S3). For example, of the 29 analogs of compound 3, 23
were active against ecNadD and 24 were active against baNadD,
whereas all 18 analogs of compound 1 turned out to be inhibitors
of bothenzymes.Notably, among42analogsof compound15, 23
compounds were confirmed as baNadD inhibitors, but only 2
compounds had an appreciable inhibitory effect on ecNadD.
Overall, an observed frequent occurrence of analogs of
compounds 1 and 3 that are active against both divergent
members of NadD family supports the possibility of developingChemistry & Biology 16, 849–861, August 28, 2009 ª2009 Elsevier Ltd All rights reserved 851
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Characterization of Bacterial NadD Inhibitorsbroad-spectrum NadD inhibitors. Although all the analyzed
analogs were selected only on the basis of structural similarity
(without any attempts of their rational improvement), many of
themdisplayed amoderate improvement of inhibitory properties,
comparedwith the original compounds. For example, 10 analogs
of compounds 1 and 3 had improved activity against ecNadD,
and22had improvedactivity againstbaNadD, pointing thepossi-
bility towards their further optimization. IC50 values against
ecNadD and baNadD determined for a subset of 33 compounds
representing all three chemotype ranged from lowmicromolar to
>200 mM (Table S3). Comparative analysis of these data revealed
an appreciable correlation (r = 0.79) of the inhibitory properties of
these compounds against both target enzymes over the entire
subset (Figure 3). The strongest correlation was observed for
the compounds from the most active class 1 (r = 0.98).
Toassesspotential selectivity of these inhibitors against bacte-
rial targets, several of the most active representatives of each
chemotype were tested for their ability to inhibit human counter-
target enzymes (hsNMNAT-1-3). These assays were performed
at 100 mMconcentration of the compounds (i.e., in the conditions
leading to > 90% inhibition of bacterial NadD enzymes). Remark-
ably, none of the tested compounds displayed any appreciable
inhibitory activity against the three human isozymes (<5% for
hsNMNAT-1 and hsNMNAT-3, and <10% for hsNMNAT-2).
These compounds displayed the same efficacy and specificity
when tested at a higher concentration of BSA (1 mg/ml) in the
assay, which is a common test to eliminate promiscuous inhibi-
tors (Coan and Shoichet, 2007; Shoichet, 2006). Overall, the
observed antibacterial selectivity and versatility of the analyzed
inhibitors further support NadD as a promising target for the
development of potential broad-spectrum antibiotics.
Effects of NadD Inhibitors on Bacterial Cell Growth
The antibacterial activity of selected NadD inhibitors was as-
sessed by their ability to suppress the growth of model gram-
negative (E. coli) and gram-positive (B. subtilis) bacteria in liquid
Figure 3. Correlation Analysis of IC50 Values for Classes 1, 3, and 15
Compounds
The analysis was restricted to compounds with IC50 values <0.2 mM and was
computed on the assumption that both IC50 values for E. coli and B. anthracis
NadDs follow a Gaussian distribution.852 Chemistry & Biology 16, 849–861, August 28, 2009 ª2009 Elsevculture. To establish conditions potentially maximizing the effect
of NadD inhibition in an E. coli model, we used a DnadA mutant
strain with disrupted de novo NAD synthesis. To further restrict
the flux of NaMN (the committed substrate of the NadD target
enzyme), we performed the growth studies on the experimentally
established lowest concentration of Nam (0.4 mM) supporting the
growth of this diagnostic strain onminimalmedia. In these condi-
tions, many of the selected NadD inhibitors of classes 1 and 3
showed an appreciable growth suppression effect at 100 mM
(Figure 4A and Table S3). To assess the extent of ‘‘on-target’’
(NadD-dependent) versus ‘‘off-target’’ (nonspecific) antibacterial
effects of these compounds, we used a derivative of the same
E. coli strain containing an overexpression plasmid vector with
the E. coli nadD gene. The growth of this strain in the presence
of selected inhibitors was compared to an isogenic control strain
containing the same plasmid vector overexpressing a house-
keeping gapA gene (unrelated to NAD synthesis). As shown in
Figures 4C and 4D, overexpression of ecNadD suppressed the
antibacterial activity of the tested representatives of NadD inhib-
itors of classes 1 and 3. On the other hand, the bactericidal effect
of the compound 15_11 (Table 1) was essentially the same in
both the NadD-overexpressing and control strain (Figure S3),
suggesting that this effect is largely nonspecific (NadD indepen-
dent). An alternative interpretation that the on-target activity of
15_11 is too high to be suppressed by NadD overexpression
appears unlikely, as the in vitro inhibitory properties of this
compound are below average (IC50, ecNadD 200 mM). On the
basis of the structure of this compound, one may expect its
hydrolysis in the medium to benzoate, a compound known to
have a general and nonspecific antibacterial activity. On the
basis of a combination of these observations and consider-
ations, we excluded compounds of the class 15 from further
analysis. An appreciable antibacterial activity was also observed
for several analogs of compounds 1 and 3 against the model
gram-positive bacteria B. subtilis (Figure 4B and Table S3). Inter-
estingly, the antibacterial effect of tested compounds in B. sub-
tilis was manifested by delayed growth, in contrast to E. coli.
where it was largely a decreased final cell density (Figure 4B).
Although establishing a rationale for this difference and confirm-
ing the actual target in gram-positive bacteria remain to be
accomplished, the growth-suppression data shown in Figure 4
and Table S3 indicate that NadD inhibitors may indeed function
as broad-spectrum antibiotics.
We further determined MIC for active compounds 3_02, 3_05,
3_15, 3_23, and 1_03 against B. anthracis sterne, B. subtilis, and
E. coli. A general correlation was observed between NadD inhi-
bition and antibacterial activity, although it was less pronounced
in E. coli (Table 1). Cell wall impermeability of gram-negative
bacteria could be a major determinant of such weaker suscepti-
bility. Notably, some of the less efficient ecNadD inhibitors (e.g.,
3_23 and 15_11) showed a relatively strong antibacterial activity
against E. coli. This observation may reflect the existence of
additional targets affected by these compounds (see also
Figure S3), nonspecific or even sharing some common features
with NadD (Moro, et al., 2009).
Mechanistic and Structural Analysis of NadD Inhibition
Representatives of both classes 1 and 3 of efficient NadD inhib-
itors were selected for detailed kinetic characterization andier Ltd All rights reserved
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ters were obtained for compounds 1_02 and 3_02 against ec-
NadD and baNadD with respect to each substrate ATP and
NaMN (Table 2 and Figure S1). A preliminary assessment of all
kinetic profiles revealed a mixed-type inhibition, as indicated
by a >1 values obtained by fitting initial rates to a general inhibi-
tion model (see Equation 2 in Experimental Procedures). Despite
the observed complex behavior preventing a straightforward
mechanistic interpretation, the obtained data showed a substan-
tial similarity in the inhibitory properties of both compounds with
respect to both target enzymes.
The 3D structure of the complex of baNadD, cocrystallized
with compound 3_02 and solved at 2.0 A˚ resolution, revealed
its binding in the active-site area mostly through van der
Waals interactions. The planar compound stacks against two
aromatic residues, Trp116 and Tyr112 (baNadD numbering),
and is also in contact with Met109 and Phe103 (Figure 5A).
Although there are a few water-mediated indirect interactions
between 3_02 and the enzyme, there is no direct intermolecular
hydrogen-bond in-teraction. A comparison with the 3D struc-
ture of baNadD complexed with the NaAD product solved in
this study at 2.2 A˚ resolution and with the recently reported
apo-baNadD structures (Lu, et al., 2008; Sershon, et al.,
2009) provided additional insights to the structural mechanism
of inhibition. This comparison revealed that the bound com-
pound 3_02 partially overlaps with the nicotinosyl binding site
and would interfere with NaMN substrate binding (Figure 5B).
Figure 4. Growth Inhibition of Model
Bacteria and Validation of NadD Target
(A and B) Effect of inhibitors of class 3 (100 mM for
E. coli and 50 mM for B. subtilis) on cell growth
as reflected in changes of the optical density at
600 nm.
(C and D) Overexpression of NadD in E. coli
DnadA, nadD+ (red) increases resistance to inhib-
itors 3_15 (C) and 1_03 (D) compared to a control
strain overexpressing enzyme GapA, unrelated
to NAD (blue). Inhibitors were tested at%100 mM
because of solubility issues at higher concentra-
tions. Results are shown as mean ± SD and are
representative of two or more experiments.
In particular, inhibitor binding would
potentially block the critical stacking
interaction between the side-chain of
the conserved Trp116 residue with the
pyridine ring of the NaMN substrate
(Olland, et al., 2002; Zhang, et al.,
2002). This interference may contribute
to a competitive aspect of the observed
mixed-type inhibition.
The structure comparison also re-
vealed a substantial difference between
the active-site conformations in the
baNadD-3_02 and baNadD-NaAD com-
plexes. Moreover, the active-site confor-
mation in the baNadD-3_02 complex
is more similar to apo-baNadD (rmsd
between Ca atoms 0.77 A˚) than to the
baNadD-NaAD complex (rmsd of 1.32 A˚). The major conforma-
tional differences occur in the regions that are involved in
NaMN binding—that is, residues 42–48 (loop connecting b2
and a2), 105–126 (helix a4), and the loop between b5 and b6
(residues 131–149) (Figure 5B). It is tempting to speculate that,
in addition to interfering with NaMN substrate binding, the inter-
actions between the inhibitor and baNadD may partially ‘‘lock’’
the enzyme active site in the catalytically impaired apo-like
conformation. This hypothetical mechanismmay provide a ratio-
nale for the observed, largely noncompetitive mode of inhibition
described above.
The baNadD enzyme has a tendency to form a homodimer, as
observed in the crystal structure of both apo-form and its
complex with substrate (Figure 5C) and as confirmed by size-
exclusion chromatography and analytical ultracentrifugation
(AUC) (data not shown). Inspection of baNadD-3_02 complex
crystal packing shows that, although the native dimer interface
is preserved, an additional dimer interface, related by a two-
fold noncrystallographic symmetry similar to that of the ‘‘hand-
shake’’ dimer observed in B. subtilis NadD (Olland, et al., 2002)
is also present, resulting in a tetrameric appearance (Figure 5D).
The 3_02 inhibitor binding site is located at this handshake
dimer interface. Because the compound binds at a site between
two baNadD monomers related by a pseudo-two-fold sym-
metry, the two symmetrical orientations of 3_02 cannot be distin-
guished. Therefore, we modeled 3_02 in both orientations, each
with half occupancy (Figure 5E).Chemistry & Biology 16, 849–861, August 28, 2009 ª2009 Elsevier Ltd All rights reserved 853
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Characterization of Bacterial NadD InhibitorsTable 1. Inhibition of Target Enzymes and Antibacterial Activity of Selected Compounds
IC50
a (mM) MIC50
b (mM)
Compound Structure ecNadD baNadDc E. coli B. anth B. subt
3_05 20 9 80 20 10
3_15 51 12 160 20 30
3_02 65 36 160 80 80
3_17 170 >200 80 >160 >160
1_03 18 33 >80 15 10
1_02 15 25 >80 NA NA
3_23 >200 63 40 >80 >80
15_11 191 98 <100
c
NA <50
c
a Inhibitory efficiency of selected compounds (representative of classes 1, 3, and 15) for two target enzymes, ecNadD and baNadD, is illustrated by IC50
values.
b Antibacterial activity of the same compounds against gram-negative (E. coli) and gram-positive (B. subtilis and B. anthracis) model species is re-
flected by MIC50 values (the lowest concentration of compound causing more than 50% growth inhibition). Representative dose-response curves
for B. subtilis and B. anthracis are provided in Figure S4.
cOnly single-point high estimates of MIC50 values were determined (70% growth inhibition at 100 mM for E. coli, and 96% inhibition at 50 mM for
B. subtilis) for a representative of the class 15 that displayed mostly off-target antibacterial activity in E. coli model; NA, not assayed.Although additional interactions between the compound 3_02
and the adjacent baNadD subunit at the handshake dimer
interface were observed in the crystal structure, it is unlikely854 Chemistry & Biology 16, 849–861, August 28, 2009 ª2009 Elsevthat such interactionswould contribute to the inhibition observed
in our assay conditions. Moreover, AUC data did not reveal any
changes in the oligomerization state of the protein in presence ofier Ltd All rights reserved
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Characterization of Bacterial NadD InhibitorsTable 2. Inhibitory Parameters of Representative Compounds from Two Chemotypes
Inhibitor 3_02 1_02
Substrate NaMN ATP NaMN ATP
Ki (mM) a Ki (mM) a Ki (mM) a Ki (mM) a
baNadD 18 ± 4 2.4 32 ± 5 5.5 9 ± 3 2.3 10 ± 2 2.9
ecNadD 25 ± 9 2.5 21 ± 9 2.4 8 ± 3 7.2 5 ± 1 7.1
The apparent values of inhibitory parameters (Ki and a) of two compounds (3_02 and 1_02) were determined for both enzymes by fitting the kinetic data
to the general equation for the mixed-model inhibition (Lyon and Atkins, 2002; see Experimental Procedures for details). The data were collected by
varying the concentration of an inhibitor and one of the two substrates (NaMN or ATP) at fixed concentration of another substrate (0.5 mM ATP or
NaMN).the inhibitor. Therefore, the contribution of the handshake dimer
interface to baNadD inhibition by 3_02 should be negligible
under the assay conditions. This conclusion is consistent with
the fact that ecNadD, being monomeric both in the crystal struc-
ture and in solution, exhibits essentially the same inhibitory prop-
erties in the presence of 3_02, including the same mixed-type
mode and similar kinetic parameters.
Notably, the three most flexible regions in baNadD mentioned
above also correspond to the regions that deviate the most
from the hsNMNAT structure (Zhou, et al., 2002) (Figure S2).
Comparison of human NMNAT structures (as represented by
hsNMNAT-1; Zhou, et al., 2002) with various baNadD complexes
indicated that hsNMNAT active site conformation is much closer
to the product-bound conformation of baNadD than to the apo
form of baNadD. No significant conformational change has
been observed between the apo and ligand bound human
NMNAT enzymes (Garavaglia, et al., 2002; Zhang, et al., 2003;
Zhou, et al., 2002). Therefore, the active site of hsNMNAT, being
quite dissimilar from the apo or inhibitor-bound baNadD, ap-
pears unable to accommodate or specifically interact with inhib-
itor 3_02 (Figure S2). This interpretation is indirectly supported by
the results of comparative virtual docking performed for the three
classes of active compounds against ecNadD, baNadD, and
hsNMNAT-1 (see Supplemental Data). The docking energies
for the human enzyme consistently have the least favorable
scores compared to the energies obtained for ecNadD and
baNadD, especially in the van der Waals energy terms, suggest-
ing that the overall shape of the binding region in hsNMNAT is
sufficiently different to allow for selective inhibition of bacterial
enzymes.
DISCUSSION
In earlier studies, we used a comparative-genomics approach to
identify NAD cofactor biosynthesis as a target pathway for devel-
opment of new anti-infective therapies (Gerdes, et al., 2002;
Osterman and Begley, 2007). The NadD enzyme was chosen
as one of themost attractive targets within this pathway because
of its nearly universal conservation in bacterial pathogens and
because its essentiality was directly confirmed in a number of
model bacteria (Gerdes, et al., 2002). A comparative enzymatic
and structural analysis revealed substantial differences between
bacterial enzymes and their human counterparts, opening an
opportunity for development of selective NadD inhibitors. The
fact that no drugs are known to act on NadD further contributesChemistry & Biology 16, 8to this choice of a target in the context of the growing challenge
of multidrug-resistant bacterial pathogens.
In the current study, an integrated structure-based approach
was employed to identify small-molecule compounds selectively
inhibiting enzymes of the NadD family with a potential broad
spectrum of antibacterial activity. By combining computational
screening of a virtual compound library with experimental testing
of inhibitory and antibacterial activity of selected compounds
and their analogs, we have identified and characterized two
classes of inhibitors with distinct chemical scaffolds (chemo-
types) possessing a number of desired properties (Table 1).
Our approach to in silico screeningwas based on selective tar-
geting of those active site residues that are highly conserved
among bacterial NadD enzymes, yet quite distinct from the
human countertarget enzymes (Zhang, et al., 2002; Zhou,
et al., 2002). A focused targeting of a nicotinosyl-binding site
(as opposed to an adenosyl-binding site) was also aimed to
exploit the functional differences between the NaMN-preferring
bacterial NadD and human enzymes with dual specificity for
NaMN and NMN substrates (Berger, et al., 2005; Sorci, et al.,
2007).We also took advantage of the large conformational differ-
ences between the apo and substrate-bound enzymes by
specifically targeting the enzyme active site in the apo form so
that the inhibitors would stabilize the enzyme in a catalytically
impaired conformation.
The obtained results supported the efficiency of this strategy.
First, we observed an appreciable correlation between inhibi-
tory properties of compounds against two divergent members
of the NadD family, from gram-negative (ecNadD) and gram-
positive bacteria (baNadD), even at the level of the primary
experimental testing of 300 compounds (Table S1). This
trend was even more apparent in the comparison of inhibitory
properties of analogs of the three compounds (1, 3, and 15)
selected for detailed characterization (Figure 3 and Table S3).
These observations indicate that the level of structural conser-
vation in the active sites of divergent representatives of the
NadD family provides a potential for developing broad-spec-
trum inhibitors. At the same time, the three selected chemo-
types showed no appreciable activity against human counter-
targets. This finding validated another premise of this study,
that the distinction between bacterial and human enzymes is
sufficient for the development of selective (bacterial-specific)
NadD inhibitors.
Although the affinity of the best inhibitors identified so far (IC50
in 4–30 mM range; see Table 1 and Table S3) is not sufficient for
them to be considered as candidate drugs, we were able to use49–861, August 28, 2009 ª2009 Elsevier Ltd All rights reserved 855
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druggability in the cell. The essentiality of the nadD gene previ-
ously established by genetic techniques does not, by itself, guar-
antee that inhibition of the NadD enzyme in the cell is possible
and may indeed suppress the bacterial growth. Moreover, the
antibacterial activity of the analyzed compounds observed in
gram-negative (E. coli) and gram-positive (B. subtilis) model
systems (Figure 4), while being encouraging, could be due to
Figure 5. Structure of baNadD in Complex
with Inhibitor 3_02 and Comparison with
Product-Bound baNadD Structure
(A) Interactions between inhibitor (magenta) and
baNadD. The two baNadD monomers are colored
gold and gray, respectively. Ca traces of baNadD
are shown. Protein residues that interact with
3_02 are shown as sticks. Water molecules are
shown as small red spheres.
(B) Superimposition of baNadD-NaAD complex
structure (cyan) with the inhibitor (3_02) bound
structure (magenta). The bound product NaAD
and inhibitor 3_02 are shown as blue and magenta
sticks, respectively.
(C) Overall structure of baNadD dimer (cyan and
blue subunits) is shownwith bound NaAD product.
The orientation of this dimer is similar to mono-
mers a and b in Figure 5D.
(D) The tetrameric arrangement of Bacillus
anthracis NadD-3_02 complex in the crystal. Two
baNadD dimers are displayed. Only one orienta-
tion of the inhibitor 3_02 (in sticks) is shown in
each binding site.
(E) The 2Fo-Fc different electron density for the
bound inhibitor 3_02. The two orientations of the
inhibitor are shown in magenta and yellow, re-
spectively.
some effects other than inhibition of the
NadD enzyme. We used an E. coli model
system to test whether the observed
growth suppression was indeed due to
the ‘‘on-target’’ action of representative
NadD inhibitors. As illustrated in Figures
4C and 4D and Figure S3, overexpression
of the target nadD gene substantially
increased resistance of this strain toward
compounds of classes 1 and 3 (but not
15). This finding provided a direct
evidence of the on-target action of these
compounds, in contrast to the tested
compounds of class 15, whose antibac-
terial activity appears to be largely due
to unknown off-target effect(s). These
data directly validated the NadD enzyme
as a drug target amenable to inhibition
in the cell, which is leading to growth
suppression.
It is important to emphasize that this
general conclusion holds true regardless
of whether further improvement of the
currently selected compounds would or
would not produce sufficiently potent antibacterial agents. The
major goal of the present study, to assess the druggability of
NadD target, dictated the choice of a genetically tractable model
system of E. coli. Whether the activity of the same compounds
against B. subtilis is also due to NadD inhibition remains to be
tested, especially since the observed type of growth suppres-
sion in B. subtilis culture is different from that in E. coli (growth
delay versus decreased final cell density).856 Chemistry & Biology 16, 849–861, August 28, 2009 ª2009 Elsevier Ltd All rights reserved
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inhibitors. This seemed particularly important as the steady-
state kinetic analysis of the representative compounds of both
classes 1 and 3 revealed a mixed-type inhibition with a strong
noncompetitive component. To assess inhibitor binding mode(s)
and to obtain a basis for rational improvement of the inhibitors,
we attempted cocrystallization of both bacterial NadD enzymes
with a panel of compounds of classes 1 and 3. The structure of
baNadD in complex with the compound 3_02 reported here
confirmed that this inhibitor indeed binds in the active site
area partially overlapping with the targeted NaMN substrate
binding site (Figure 5B). The experimentally determined location
of the inhibitor is adjacent to that predicted by the in silico
docking (Figure S5). Moreover the conformation of the baNadD
active site in this complex is drastically different from its
product-bound conformation, which is also reported in this
study. In fact, the inhibitor binding appears to stabilize the
baNadD conformation in its apo form, incompatible with
substrate binding and catalysis (Lu, et al., 2008; Sershon,
et al., 2009). Inhibitor interference at the level of substrate
binding and the stabilization of alternative enzyme conformation
may provide a rationale for the observed complex (mixed-type)
kinetics of inhibition. Although the actual inhibitory mechanism is
not fully clear, the obtained structural information is useful for
further inhibitor optimization via structure-based design and
synthesis of analogs. For example, engineering additional func-
tional groups that may form specific hydrogen-bond interactions
with the enzyme should enhance the binding affinity of the
compound.
SIGNIFICANCE
In this study, we have demonstrated the feasibility of devel-
oping NadD inhibitors against divergent members of NadD
family with strong selectivity for bacterial (versus human)
enzymes. Some of the selected inhibitors displayed an
appreciable antibacterial activity in both gram-positive and
gram-negative model systems. The established ‘‘on-target’’
action of these inhibitors confirmed that NadD is a tractable
drug target for the development of novel antibacterial
agents. The cocrystal structure of the compound 3_02 in
complex with baNadD confirmed its binding at the active
site and provided guidelines for inhibitor improvement.
These results, taken together, illustrate the power of com-
bining comparative genomics with a structure-based ap-
proach for the development of new classes of anti-infective
agents.
EXPERIMENTAL PROCEDURES
Materials
All common buffers and reagents were purchased from Sigma-Aldrich. Small
molecules selected from in silico screening were obtained from Chembridge,
Specs.net and ChemDiv Inc.
In Silico Database Screening
The substrate binding site of ecNadD (Zhang, et al., 2002) was selected as the
target for docking. System preparation involved analysis of the target protein
structure, selection of inhibitor binding site, and generation of the sphere setChemistry & Biology 16, 8used to direct the docking (see Supplemental Data for details). All database
screening calculations were carried out with DOCK 4.0 (Krumrine, et al.,
2003; Kuntz, et al., 1982). The primary screening was performed on a 3D data-
base of over 1 million low-molecular-weight commercially available com-
pounds developed in the University of Maryland Computer-Aided Drug Design
(CADD) Center (Huang, et al., 2004; Zhong, et al., 2007). Ligand flexibility was
incorporated during docking via the anchor-based search method (Ewing and
Kuntz, 1997). Compounds from the initial primary screen were docked onto the
protein according to the total ligand-protein interaction energy and were
scored on the basis of the van der Waals (vdW) attractive energies normalized
for molecular size (Pan, et al., 2003).
Top scoring compounds from the primary screen were subjected to more
rigorous secondary docking, where additional optimization of the ligand
was performed during the build-up procedure. Additionally, conformational
flexibility of ecNadD was taken into account via the inclusion of multiple
protein conformations either from the crystallographic studies (secondary
screen A) or from a molecular dynamics (MD) simulation of ecNadD
(secondary screen B). In secondary screen A, the top 20,000 scoring
compounds from the primary screening were individually docked to the three
conformations of apo ecNadD obtained from the 1k4k crystal structure. In
secondary screen B, multiple protein conformations were obtained from the
MD simulation of apo ecNadD (see Supplemental Data). The top 50,000
scoring compounds from the primary screen were then docked against five
MD-generated conformations and were ranked using the normalized total
interaction energy for each compound. The top scoring compounds from
the two separate secondary screens, totaling 500 and 1000, respectively,
were then separately subjected to the final compound selection based on
physical properties and chemical similarity. Determination of chemical
similarity and further selection of compounds were performed according to
standard procedures (Supplemental Data). Finally, a total of 529 unique
compounds were selected; of these, 307 were purchased from the commer-
cial vendors for the in vitro inhibition assay. After primary testing (see below),
three chemotypes (classes 1, 3, and 15) were selected for further analysis of
chemical analogs. A total of 89 analogs were purchased and experimentally
tested.
Kinetic Analysis of NadD and Primary Testing of Selected
Compounds
A discontinuous assay was utilized to determine the steady-state kinetics
parameters kcat and Km for NadD and for inhibitory testing of selected com-
pounds. This assay couples pyrophosphate (PPi) byproduct formation of
NaMNATase activity to colorimetric detection of free phosphate released
upon enzymatic hydrolysis.
(1) NaMN Adenylyltransferase (NaMNATase) reaction
NaMN+ATP+Mg2+/NaAD + +PPi +Mg
2+
(2) Inorganic pyrophosphatase (IPase) reaction
PPi +H2O/2Pi
Excess IPase is used to ensure rapid conversion of pyrophosphate to ortho-
phosphate so that the rate-limiting step in this system is the NaMN adenylyl-
transferase reaction. Excess inorganic phosphate also decreases the proba-
bility that observed inhibition is due to the inhibition of IPase and not the
target enzyme. We have since confirmed that the best NadD inhibitors (with
IC50 values ranging from 5 to 25 mM) did not inhibit IPase.
Steady-state kinetic analysis of ecNadD and baNadD target enzymes was
performed by varying substrate (NaMN or ATP); concentrations were 0, 10,
30, 60, 200, and 500 mM at fixed saturating concentration of second substrate
(0.5 mM). Apparent values of Km and kcat were calculated by fitting initial
rates to a standard Michaelis-Menten model using the software Prism 4
(GraphPad).
The standard inhibition assay was configured in a 96-well format for auto-
mated liquid-handling and convenient readout. Each compound was
prepared as a 10 mM stock solution in dimethyl sulfoxide (DMSO) and diluted49–861, August 28, 2009 ª2009 Elsevier Ltd All rights reserved 857
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(or 1.2 nM baNadD) in 100 mM HEPES (pH 7.5) buffer, 0.2 mM ATP, 0.07
or 0.2 mM NaMN, 10 mMMgCl2, 0.1 mg/ml bovine serum albumin, 0.2 U inor-
ganic pyrophosphatase, and 50 or 100 mM tested compound (the complete
lists of tested compounds with structure and vendor information is provided
in Tables S1 and S2). Although the use of surfactants is a common practice to
reduce the effects of promiscuous inhibitors, an observed interference of
Triton X-100 at 0.01% with our assay prompted us to include bovine serum
albumin (0.1–1 mg/ml) in the assay mixture to prevent the selection of promis-
cuous aggregating inhibitors (Coan and Shoichet, 2007). The choice of two-
fold Km(app) concentrations of both NaMN and ATP substrates was necessary
to ensure a good signal-to-noise ratio under the initial velocity phase of enzy-
matic reactions (10%–20% substrate depletion), while retaining a linear signal
response (0–15 mM PPi). The same assay setup was applied when testing
small-molecule inhibitors against human countertargets. Concentrations of
hsNMNAT-1 and hsNMNAT-2 were 3 nM, whereas hsNMNAT-3 was tested
at 15 nM. After preincubation of the enzyme with the compounds for 5 min
at room temperature, the reaction was initiated by addition of NaMN
substrate. The reaction was allowed to progress for 20 min at room temper-
ature prior to quenching by addition of 100 ml of malachite green reagent in
1.2 M sulfuric acid prepared as described by Cogan, et al. (1999). After
20–30 min incubation to allow for complex/color formation, the absorbance
in each well was measured at 620 nm using a microplate reader (Beckman
DTX-880). To account for contribution of free Pi and/or PPi (present in the
sample or released due to nonspecific hydrolysis of ATP during incubation)
as well as of background absorbance (color) of the tested compounds,
parallel reactions were run for each experimental point without addition of
NadD enzymes, and their OD620 values were subtracted from the measure-
ments of enzyme activity in their respective samples. Reaction in the pres-
ence of 2% DMSO but without inhibitory compound served as a positive
control. Each measurement was made in triplicate. On the basis of the sensi-
tivity and reproducibility of the assay, inhibition R20% was considered reli-
able. A continuous coupled assay that detected reduction of NAD+ (Kurnasov,
et al., 2002) was used for preliminary assessment of NaMNTase activity and
to corroborate kinetic parameters obtained with malachite green discontin-
uous assay.
IC50 Measurements and Ki Determination
The compounds selected on the basis of the results of primary testing were
further characterized using the malachite green end-point assay. The initial
rate of enzymatic reaction was measured at fixed NaMN and ATP concentra-
tions (equal to two-fold Km values) and various concentrations of an inhibitory
compound. The IC50 value was determined by plotting the relative NaMNA-
Tase activity versus inhibitor concentration and fitting to the equation (1) using
GraphPad Prism.
Vi =
V0
1+ ½I
IC50
(1)
V0 and Vi represent initial rates in the absence and presence of inhibitor
concentration [I].
For Ki determination, the enzyme was preincubated with various fixed
concentrations of inhibitors for 5min. The reactionwas initiated by the addition
of fixed concentration of NaMN (five-fold Km) at varying concentrations of ATP
(ranging from 0.2 to five-fold Km) and vice versa. The inhibition constant and
inhibition pattern were evaluated by fitting the data to the Michealis-Menten
rate equation (2) for general (mixed-type) inhibition (Lyon and Atkins, 2002)
with the program GraphPad Prism.
V=
Vmax½S
Kmð1+ ½IKi

+ ½S

1+ ½I
aKi
 (2)
Vmax and Km are standard Michaelis-Menten parameters, and Ki is the equi-
librium dissociation constant for the enzyme-inhibitor complex. The parameter
a defines the degree to which the inhibitor binding affects the affinity of the
enzyme for the substrate and is diagnostic of the inhibition mode, which
may be purely competitive (a > > 1), purely noncompetitive (a = 1), uncompet-
itive (a < < 1), or mixed-type (a > 1 or a < 1).858 Chemistry & Biology 16, 849–861, August 28, 2009 ª2009 ElsevSuppression of Bacterial Growth in Culture
Diagnostic E. coli strains used for growth-suppression experiments and for
target verification were prepared in the background of the E. coli K-12
BW25113 (DnadA) knockout strain with disrupted NAD de novo synthesis
pathway from the Keio collection (a gift by Dr. H. Mori, Keio University, Japan)
(Baba, et al., 2006). This strain was used in combination with one of the two
expression plasmids from the E. coli ASKA library (Kitagawa, et al., 2005)
enabling inducible overexpression of (1) the E. coli nadD gene (to test for the
increased resistance against NadD inhibitors) or (2) the E. coli gapA gene,
a housekeeping metabolic enzyme glyceraldehyde-3-phosphate dehydroge-
nase (as a negative control). Starter cultures were grown overnight in LB
medium. Cells were harvested, washed, and resuspended in the M9 minimal
growth medium containing 1% glycerol, 0.1 mM IPTG, 50 mg/l kanamicin,
35 mg/l chloramphenicol, and a limiting amount of nicotinamide (Nam,
0.4 mM). Upon reaching an optical density at 600 nm of 0.05, cells were
used to initiate growth experiments in 96-well plate at various concentrations
of inhibitors.
The bacterial growth at 37C in these (and other) experiments was moni-
tored by continuous absorbance measurement at 600 nm using an orbital
shaker/microplate reader ELx808. The area under the growth curve
(AUGC) was used to calculate the growth inhibition (Firsov, et al., 2001) and
was compared to the respective amount of DMSO. The AUGC was integrated
and calculated with GraphPad Prism 4. Growth suppression studies of B. sub-
tilis 168 (Bs168) were performed following a similar procedure in a chemically
defined medium (Rodionov, et al., 2009) containing glucose (4 g/l), tryptophan
(50 mg/l), glutamine (2 g/l), K2HPO4 (10 g/l), KH2PO4 (6 g/l), sodium citrate
(1 g/l), MgSO4 (0.2 g/l), K2SO4 (2 g/l), FeCl3 (4 mg/l), and MnSO4 (0.2 mg/l).
B. anthracis was grown in the same minimal medium containing additionally
10% LB medium for robust growth.
Selected compounds causing an appreciable growth inhibition were sub-
jected to minimal inhibitory concentration (MIC) determination in a series of
dilutions from 160 mM down to 2.5 mM. The high concentration limit was deter-
mined by solubility problems observed for many compounds. In this concen-
tration range, only some of the analyzed compounds displayed >90% growth
inhibition. Therefore, for consistency, the value of MIC was defined as the
lowest concentration of compound that caused more than 50% growth inhibi-
tion (as determined by AUGC method).
Purification and Crystallography
The expression and purification of ecNadD and baNadD were performed as
described elsewhere (Zhang, et al., 2002). The human proteins hsNMNAT-1,
hsNMNAT-2, and hsNMNAT-3 were also expressed in E. and purified as re-
ported elsewhere (Gerdes, et al., 2002; Zhang, et al., 2003; Zhou, et al.,
2002). For crystallization, baNadD was first purified with Ni Sepharose HP
column (GE Healthcare) and treated with TEV protease overnight before being
passed through the Ni column again to remove the 6xHis tag. The tag-free
protein was further purified by a Resource Q anion exchange column and
Superdex 75 16/60 gel filtration column (GE Healthcare). The purified protein
was concentrated to 20 mg/ml before crystallization. The baNadD-NaAD
complex crystal was obtained in a hanging drop vapor diffusion setup in the
presence of 10 mM NaAD at 20C. The reservoir contained 20% PEG 3350
and 0.2 M calcium acetate. The cocrystals of baNadD with compound 3_02
were obtained in the presence of 1 mM 3_02 in conditions similar to those
for the NaAD complex crystals. Before data collection, the baNadD-NaAD
cocrystals were transferred to a cryoprotectant solution containing 40%
PEG 3350 and 0.2 M calcium acetate before being frozen in liquid nitrogen.
The baNadD-3_02 cocrystals were not stable in such a cryoprotectant solu-
tion; therefore, a different cryprotectant containing 20% PEG 3350, 0.2 M
calcium acetate, and 15% DMSO was used to stabilize the inhibitor complex
crystals before freezing them liquid nitrogen. The X-ray diffraction data were
collected on a RAXIS IV2+ image plate detector with a FR-E Superbright
X-ray generator coupled with Osmic VariMax optics. The data were processed
with HKL2000 package (Otwinowski and Minor, 1997). The baNadD-NaAD
complex structure was first determined by the molecular replacement
methods in the CNS package (Brunger, et al., 1998) using the B. subtilis
NadD structure (Olland, et al., 2002) as the initial search model (pdb code
1kam). The baNadD inhibitor complex was subsequently solved with molec-
ular-replacement methods, as implemented in the program Molrep (Vaginier Ltd All rights reserved
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cluding the NaAD ligand) as the search model. Both structures were refined
with REFMAC (Murshudov, et al., 1997) in the CCP4 package (CCP4, 1994)
and were deposited in the Protein Data Bank with accession codes 3E27
and 3HFJ, respectively. The data collection and refinement statistics for
both structures are listed in Table 3. The models were analyzed by MolProbity
program (Lovell, et al., 2003).
Analytical Ultracentrifugation
Sedimentation equilibrium experimentswere performed in aProteomeLabXL-I
(BeckmanCoulter) analytical ultracentrifuge. Protein samples at 0.22 mg/ml
concentration were loaded in 6-channel equilibrium cells and spun in an
An-50 Ti 8-place rotor at 15,000 and 18,000 rpm, at 20C for 24 hr for each
speed. The sample buffer contained 20 mM HEPES (pH 7.4) and 5% DMSO.
Small-molecule inhibitors were tested at 50 mM. Absorbance profiles were
acquired at 280 nm and analyzed with HeteroAnalysis software (National
Analytical Ultracentrifugation Facility at the University of Connecticut).
Apparent molecular weight (Mw) was determined by fitting the experimental
datawith the Ideal equilibriummodel. If the apparentMwwashigher thancalcu-
lated theoretical Mw for the monomer, the data were fitted using Monomer-
Nmer or Monomer-Nmer-Mmer equilibrium models.
Table 3. Crystal Data and Refinement Statistics
Data sets baNadD$product baNadD$3_02
Data Statistics
Space group P212121 P21212
Unit cell (A˚) a = 41.8,
b = 137.41,
c = 143.97
a = 88.79,
b = 97.53,
c = 44.30
Resolution (A˚) 50–2.2 50–2.0
Total observations 157926 113171
Unique Reflections 43353 26467
Completeness (outer shell) (%) 98.8 (89.9) 99.9 (100.0)
Rsym (outer shell)
a 0.085 (0.555) 0.037 (0.279)
I/d (outer shell) 15.9 (2.0) 36.8 (5.4)
Refinement
Rwork
b 0.206 0.205
Rfree
c 0.276 0.266
Rmsd bond length (A˚) 0.011 0.012
Rmsd bond angle () 1.49 1.44
Monomers/asymmetric unit 4 2
Protein atoms 6196 3102
Water molecules 494 309
Ligand atoms 180 53
Average B-factors (A˚2)
Protein 32.4 28.0
Ligands 24.4 41.1
Water 39.9 34.4
Ramachandran Plot
Favored region (%) 97.0 98.7
Allowed region (%) 99.3 100.0
aRsym = Shkl Sj jIj – < I > j / Shkl SjjIjj.
b Rwork = ShkljFo – Fcj / ShkljFoj, where Fo and Fc are the observed and
calculated structure factors, respectively.
c Five percent randomly selected reflections were excluded from refine-
ment and used in the calculation of Rfree.Chemistry & Biology 16, 8ACCESSION NUMBERS
Coordinates have been deposited in the Protein Data Bank with accession
codes 3E27 and 3HFJ.
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